R&D/Clinical Trials

Radiopharmaceutical logistics is fundamentally different from traditional pharmaceutical supply chains.

Incyte reports sustained 24-week efficacy and consistent safety data for Opzelura cream in moderate atopic dermatitis, supporting interest in nonsteroidal topical therapies for long-term disease control.

In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive global license for a precision siRNA therapy targeting a key genetic driver of MASH, Zentalis Pharmaceuticals announces the first patient dosed in a Phase III trial and Brooke Ervin argues that translating real-world evidence into commercial and clinical impact in urology requires more than access to data.

Zentails announced the first dosage of Azenosertib administered in its phase III Aspenova trial to test azenosertib vs chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer.

Getting from insight to impact requires more than access to information.

FDA clears Cellenkos’ IND for CK0802, enabling a mid-stage trial in steroid-refractory GVHD.

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager cizutamig to expand its immunology pipeline.

FDA advisory panel backs Truqap combination in PTEN-deficient prostate cancer, signaling potential expansion into biomarker-defined mHSPC population with limited treatment options.

Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine.

Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

Eli Lilly to acquire Ajax Therapeutics in up to $2.3B deal, adding a first-in-class Type II JAK2 inhibitor to strengthen its blood cancer pipeline.

MaxCyte’s CEO explains the various ways CGT is impacted by new technologies and methods of treatment delivery.

MaxCyte CEO Maher Masoud discusses how new treatment methods are providing greater control of the therapy’s safety profile.

Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.

Eli Lilly’s acquisition of Kelonia Therapeutics signals a potential shift in the cell therapy landscape, as in vivo approaches aim to overcome the cost, complexity, and access limitations of traditional CAR-T treatments.

Samsung Bioepis’ SVP and head of US commercial discusses the pricing, regulatory, and broader issues impacting the biosimilars market.

ARS Pharmaceutical’s CEO discusses how reformulating drugs and updating delivery design can improve the rate of patient adherence to medication.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, discusses how the Tecvayli and Darzalex Faspro combination delivers deep, durable responses, along with its rapid FDA review.

Eli Lilly releases new safety data after FDA requested additional data to conduct extensive post-approval safety studies for Foundayo, including long-term monitoring of cardiovascular, liver, and thyroid cancer risks.

Biotech financing activity this week underscores strong investor backing for platform-driven innovation, with capital flowing into ADC development, precision immunology, multi-cancer diagnostics, and non-invasive oncology technologies aimed at addressing persistent gaps in care.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, notes select influences of how the Phase III clinical testing was conducted.

Imran Khan, Md, PhD, Vice President of U.S. medical affairs for hematology, oncologist, Johnson & Johnson, touched on Tecvayli plus Darzalex Faspro reducing the risk of disease progression or death by 83%, and what that signals for patients.

Thomas Newcomer of Samsung Bioepis discusses how certain classes of drugs don’t have enough biosimilars in development and the impact that this can have in the coming years.